PhenoPath, PLLC

Diagnoses you can count on®

PhenoPath, PLLC is a physician-owned specialty pathology practice and reference laboratory providing diagnostic and contract research services to pathology and oncology practices, hospitals, biopharmaceutical companies and research institutions in the U.S., Canada and around the world.

PhenoPath’s test menu includes a broad array of state-of-the-art immunohistochemistry, flow cytometry, fluorescence in situ hybridization and molecular assays as well as chromosome analysis.

Which PD-L1 test should I order? Click here for more information.

Latest News

  • Phenomena v19.1 (Spring 2016)

    PhenoPath at USCAP, Open House Event, PD-L1 (22C3 and 28-8) and EGFR T790M testing at PhenoPath, BAP1 and P16 FISH in malignant mesothelioma, and...

    Read More »
  • PD-L1 IHC 22C3 pharmDx

    PhenoPath is proud to announce the release of FDA-approved PD-L1 IHC 22C3 pharmDx, for the semi-quantitative assessment of PD-L1 expression in non-small...

    Read More »
  • Roche cobas® EGFR Mutation Test

    Effective Tuesday, November 17, 2015, PhenoPath is pleased to offer the Roche cobas® EGFR Mutation Test (v2), which will replace PhenoPath’s...

    Read More »

PhenoPath, PLLC

About PhenoPath


Medical Staff

Executive Staff

Licensing & Accreditation


Test Menu


Diagnostic Services

Clinical Setting

Educational Media

Contact Diagnostic Services

BioPharma Services

Clinical Trial Services

R & D Services



Contact BioPharma Services

News & Info

Company News



Upcoming Events

Contact Us

Dept. Inquiries

Submit a Case

Order Supplies